Stroke

Neurology
32
Pipeline Programs
30
Companies
50
Clinical Trials
6 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
2
11
0
7
9
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
267%
Small Molecule
133%
+ 93 programs with unclassified modality

On Market (3)

Approved therapies currently available

Takeda
ACTOSApproved
pioglitazone
Takeda
oral1999
Ipsen
DYSPORTApproved
botulinum toxin type a
Ipsen
Acetylcholine Release Inhibitor [EPC]injection2009
U
REOPROApproved
abciximab
Unknown Company
injection1994

Competitive Landscape

40 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
17 programs
2
3
2
AggrenoxPhase 41 trial
MetamizolePhase 4Small Molecule1 trial
alteplasePhase 31 trial
optional ASA as comedicationPhase 31 trial
tenecteplasePhase 31 trial
+12 more programs
Active Trials
NCT02229799Terminated265
NCT01671007Completed10,471Est. Dec 2019
NCT01937377Completed200Est. Apr 2019
+14 more trials
City Therapeutics
City TherapeuticsMA - Cambridge
6 programs
1
Tongfu capsulesPhase 41 trial
Blood pressure management of Systolic Blood Pressure to maintain target range +/- 10 mmHgN/A1 trial
High Intensity Gait TrainingN/A1 trial
Isokinetic ExercisesN/A1 trial
PEERN/A1 trial
+1 more programs
Active Trials
NCT05645861Active Not RecruitingEst. Feb 2026
NCT04870619CompletedEst. Sep 2023
NCT07106619RecruitingEst. Mar 2026
+3 more trials
Pfizer
PfizerNEW YORK, NY
4 programs
1
1
1
DonepezilPhase 41 trial
traxiprodilPhase 21 trial
Donepezil and self-generated memory trainingPhase 11 trial
ApixabanN/A1 trial
Active Trials
NCT04808934Withdrawn0Est. Dec 2020
NCT00457769Unknown18Est. Dec 2021
NCT00073476Terminated300Est. Feb 2005
+1 more trials
Takeda
TakedaTOKYO, Japan
1 program
1
1
pioglitazonePhase 31 trial
Active Trials
NCT00091949Completed3,876Est. Nov 2015
Ipsen
IpsenChina - Tianjin
1 program
1
Botulinum toxin type APhase 41 trial
Active Trials
NCT02321436Completed42Est. Mar 2016
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
Danhong InjectionPhase 41 trial
Active Trials
NCT02152280UnknownEst. Dec 2015
DS
4 programs
2
1
warfarin tabletsPhase 31 trial
SUN13837Phase 21 trial
piclozotan low dosePhase 21 trial
Addressing Real-world Anticoagulant Management Issues in StrokeN/A
Active Trials
NCT02258880Withdrawn0Est. May 2016
NCT00272909Terminated43Est. Jan 2007
NCT00781391Completed21,105Est. May 2013
Penumbra
PenumbraALAMEDA, CA
4 programs
1
1
ThrombectomyPhase 31 trial
Penumbra SystemPhase 21 trial
Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapiesN/A1 trial
Penumbra SystemN/A1 trial
Active Trials
NCT01092819Completed150Est. Dec 2013
NCT00785161Completed289Est. Dec 2010
NCT00334061Completed125Est. Nov 2007
+1 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
AbciximabPhase 3Monoclonal Antibody5 trials
Active Trials
NCT00178451Withdrawn0
NCT00420030Completed80Est. Jun 2009
NCT00354406Completed110Est. Dec 2008
+2 more trials
Bayer
5 programs
1
Repinotan HClPhase 21 trial
Direct Oral AnticoagulantN/A1 trial
Direct Oral AnticoagulantN/A1 trial
Systematic detection of vascular risk factors and subsequent evidence-based treatmentN/A
prolonged ECG monitoringN/A1 trial
Active Trials
NCT02470767Completed792Est. Mar 2016
NCT02559232Completed247Est. Mar 2016
NCT02204267Completed3,470Est. Oct 2020
+1 more trials
Genentech
3 programs
1
tPAPhase 21 trial
Addressing Real-world Anticoagulant Management Issues in StrokeN/A
AlteplaseN/A1 trial
Active Trials
NCT02447094Unknown300
NCT01643902Completed20Est. Dec 2015
Heidelberg Pharma
2 programs
1
Cold crystalloid infusions, 0.9%NaCl or Ringer's solutionPhase 21 trial
Time in therapeutic range of vital parametersN/A1 trial
Active Trials
NCT06367543Completed474Est. Dec 2021
NCT01669408Unknown40Est. Sep 2013
GSK
GSKLONDON, United Kingdom
1 program
1
NC-758Phase 21 trial
Active Trials
NCT00056238Completed30
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
Neu2000KWLPhase 21 trial
Active Trials
NCT04486430CompletedEst. Dec 2019
Stempeutics Research
Stempeutics ResearchIndia - Bangalore
1 program
1
Ex vivo cultured adult allogenic MSCsPhase 1/21 trial
Active Trials
NCT01091701WithdrawnEst. May 2013
PathMaker Neurosystems
1 program
1
sham DoublestimPhase 1/21 trial
Active Trials
NCT03080454CompletedEst. Mar 2018
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
AlirocumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT03507374Terminated20Est. Apr 2020
DiaMedica Therapeutics
DiaMedica TherapeuticsMINNEAPOLIS, MN
1 program
1
Recombinant human tissue kallikreinPhase 11 trial
Active Trials
NCT02868996CompletedEst. Mar 2017
Verona Pharma
Verona PharmaUK - London
10 programs
Backward Walking Treadmill TrainingN/A1 trial
Experimental group - robot assisted arm trainingN/A1 trial
Experimental treatmentN/A1 trial
G-EO SystemN/A1 trial
High intensity aerobic trainingN/A1 trial
+5 more programs
Active Trials
NCT02710773Unknown20Est. Dec 2016
NCT03590314Completed32Est. Jul 2018
NCT04323501Unknown134Est. Jun 2024
+7 more trials
NeuroLutions
4 programs
IpsiHandN/A1 trial
IpsiHand TherapyN/A1 trial
IpsiHand TreatmentN/A1 trial
Neurolutions IpsiHand SystemN/A1 trial
Active Trials
NCT07147881Not Yet RecruitingEst. Jan 2028
NCT04338971CompletedEst. Oct 2020
NCT04123808WithdrawnEst. Jun 2020
+1 more trials
Providence Therapeutics
3 programs
CO-OP KT ExposureN/A1 trial
Deconstructing Post Stroke HemiparesisN/A1 trial
Traditional CI TherapyN/A1 trial
Active Trials
NCT02597569CompletedEst. Aug 2018
NCT05993221RecruitingEst. Sep 2027
NCT02631850CompletedEst. Dec 2019
Abbott
AbbottABBOTT PARK, IL
2 programs
AMPLATZER™ PFO OccluderN/A1 trial
Amulet Left Atrial Appendage OccluderN/A1 trial
Active Trials
NCT03309332Active Not Recruiting1,214Est. Feb 2030
NCT02879448Completed1,878Est. May 2024
Alliance Pharmaceuticals
2 programs
Attention Training TechniqueN/A1 trial
pulmonary computed tomographyN/A1 trial
Active Trials
NCT06457126Not Yet Recruiting14Est. Aug 2025
NCT03106909Completed41Est. Jul 2018
Design Therapeutics
2 programs
Brain Computer Interface integrated HandyRehab platformN/A1 trial
MiraπN/A1 trial
Active Trials
NCT06076928RecruitingEst. Jan 2026
NCT06296628CompletedEst. Apr 2025
Ottobock
2 programs
RETRAINER-S1N/A1 trial
RETRAINER-S2N/A1 trial
Active Trials
NCT03171649UnknownEst. May 2018
NCT03199833UnknownEst. May 2018
MicroTransponder
MicroTransponderTX - Austin
2 programs
Vagus Nerve StimulationN/A1 trial
Vivistim SystemN/A1 trial
Active Trials
NCT02243020Completed17Est. Jun 2022
NCT01669161Completed21Est. Dec 2014
Century Therapeutics
Century TherapeuticsPHILADELPHIA, PA
1 program
An EHR-based Platform To Facilitate Outcomes and Research Methods in Cerebrovascular DiseasesN/A1 trial
Active Trials
NCT04775836Unknown300,000Est. Dec 2021
EMVision
EMVisionAustralia - Sydney
1 program
Brain ScanN/A1 trial
Active Trials
NCT06999122RecruitingEst. Nov 2026
Life & Brain
1 program
Client-centered ADL interventionN/A1 trial
Active Trials
NCT01417585CompletedEst. Dec 2012
Sensome
SensomeFrance - Massy
1 program
Clotild® Smart Guidewire SystemN/A1 trial
Active Trials
NCT04993079Completed45Est. Apr 2024

+10 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
City TherapeuticsTongfu capsules
IpsenBotulinum toxin type A
T-TherapeuticsDanhong Injection
Eli Lilly and CompanyAbciximab
Eli Lilly and CompanyAbciximab
Eli Lilly and CompanyAbciximab
Boehringer IngelheimAggrenox
PfizerDonepezil
Boehringer IngelheimMetamizole
Boehringer Ingelheimtenecteplase
PenumbraThrombectomy
Boehringer Ingelheimalteplase
Boehringer Ingelheimoptional ASA as comedication
Daiichi Sankyowarfarin tablets
Eli Lilly and CompanyAbciximab

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 188,476 patients across 50 trials

NCT04275219City TherapeuticsTongfu capsules

Safety and Efficacy of the Tong-Fu-Xing-Shen Herbal Formula for Stroke-Associated Pneumonia

Start: Mar 2019Est. completion: Dec 2021
Phase 4Unknown
NCT02321436IpsenBotulinum toxin type A

Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression

Start: Dec 2014Est. completion: Mar 201642 patients
Phase 4Completed
NCT02152280T-TherapeuticsDanhong Injection

A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke

Start: Mar 2014Est. completion: Dec 2015
Phase 4Unknown
NCT00420030Eli Lilly and CompanyAbciximab

Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock

Start: Sep 2006Est. completion: Jun 200980 patients
Phase 4Completed
NCT00354406Eli Lilly and CompanyAbciximab

Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty

Start: Apr 2006Est. completion: Dec 2008110 patients
Phase 4Completed
NCT00169819Eli Lilly and CompanyAbciximab

EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study

Start: Oct 2003Est. completion: Apr 20061,000 patients
Phase 4Completed
NCT00153062Boehringer IngelheimAggrenox

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

Start: Aug 200320,332 patients
Phase 4Completed
NCT00196690PfizerDonepezil

Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial

Start: Feb 2003Est. completion: Mar 200530 patients
Phase 4Completed
NCT02184260Boehringer IngelheimMetamizole

Efficacy and Safety of Metamizole Versus Placebo as Antithermic Therapy in the Acute Phase of Ischemic Stroke

Start: Dec 199858 patients
Phase 4Terminated
NCT04915729Boehringer Ingelheimtenecteplase

A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity

Start: Jun 2021Est. completion: Oct 20231,489 patients
Phase 3Completed
NCT02216643PenumbraThrombectomy

EndoVascular Treatment With Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke

Start: Feb 2017Est. completion: Jun 2019
Phase 3Completed
NCT02930837Boehringer Ingelheimalteplase

Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset

Start: Nov 2016Est. completion: Dec 2017120 patients
Phase 3Completed
NCT02239120Boehringer Ingelheimoptional ASA as comedication

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Start: Nov 2014Est. completion: Aug 20185,390 patients
Phase 3Completed
NCT00781391Daiichi Sankyowarfarin tablets

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

Start: Nov 2008Est. completion: May 201321,105 patients
Phase 3Completed
NCT00167765Eli Lilly and CompanyAbciximab

Abciximab in Wake-up Stroke

Start: Mar 2005Est. completion: May 200550 patients
Phase 3Terminated
NCT00091949Takedapioglitazone

Insulin Resistance Intervention After Stroke Trial

Start: Feb 2005Est. completion: Nov 20153,876 patients
Phase 3Completed
NCT00126139Eli Lilly and CompanyAbciximab

Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis

Start: Apr 2004Est. completion: May 2005100 patients
Phase 3Terminated
NCT00046228Eli Lilly and CompanyAbciximab

A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)

Start: Aug 2002Est. completion: Jan 20082,461 patients
Phase 3Completed
NCT04486430Qilu PharmaceuticalNeu2000KWL

Efficacy and Safety Study of Neu2000KWL for Acute Ischemic Stroke Patients Within 6 Hours of Onset

Start: Mar 2017Est. completion: Dec 2019
Phase 2Completed
NCT02258880Daiichi SankyoSUN13837

Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke

Start: Sep 2014Est. completion: May 20160
Phase 2Withdrawn
NCT01643902GenentechtPA

Safety of Intravenous Thrombolytics in Stroke on Awakening

Start: Jan 2013Est. completion: Dec 201520 patients
Phase 2Completed
NCT01669408Heidelberg PharmaCold crystalloid infusions, 0.9%NaCl or Ringer's solution

Prehospital COOLing 1 (PreCOOL 1)

Start: Sep 2012Est. completion: Sep 201340 patients
Phase 2Unknown
NCT00334061PenumbraPenumbra System

Study to Assess the Safety and Effectiveness of the Penumbra System

Start: Jun 2006Est. completion: Nov 2007125 patients
Phase 2Completed
NCT00272909Daiichi Sankyopiclozotan low dose

Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)

Start: Sep 2004Est. completion: Jan 200743 patients
Phase 2Terminated
NCT00073476Pfizertraxiprodil

A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

Start: Sep 2003Est. completion: Feb 2005300 patients
Phase 2Terminated
NCT00056238GSKNC-758

Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy

Start: Feb 200330 patients
Phase 2Completed
NCT00238537Boehringer IngelheimAlteplase t-PA

Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET)

Start: Aug 2001Est. completion: Apr 2007100 patients
Phase 2Completed
NCT02251197Boehringer IngelheimBIII 890 CL

Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke

Start: Jul 200197 patients
Phase 2Completed
NCT00044915BayerRepinotan HCl

Repinotan in Patients With Acute Ischemic Stroke

Start: Dec 2000Est. completion: Sep 2004782 patients
Phase 2Completed
NCT00178451Eli Lilly and CompanyAbciximab

Stroke Prevention With Abciximab in Carotid Endarterectomy

0
Phase 1/2Withdrawn
NCT03080454PathMaker Neurosystemssham Doublestim

The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke

Start: Sep 2016Est. completion: Mar 2018
Phase 1/2Completed
NCT01091701Stempeutics ResearchEx vivo cultured adult allogenic MSCs

Ex Vivo Cultured Adult Allogenic MSCs in Ischemic Cerebral Stroke

Start: Dec 2011Est. completion: May 2013
Phase 1/2Withdrawn
NCT03507374RegeneronAlirocumab

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

Start: Oct 2018Est. completion: Apr 202020 patients
Phase 1Terminated
NCT02868996DiaMedica TherapeuticsRecombinant human tissue kallikrein

An Open Label, Phase 1b, Ascending Dose Study of DM199

Start: Sep 2016Est. completion: Mar 2017
Phase 1Completed
NCT00457769PfizerDonepezil and self-generated memory training

Aricept to Improve Functional Tasks in Vascular Dementia

Start: May 2007Est. completion: Dec 202118 patients
Phase 1Unknown
NCT07147881NeuroLutionsIpsiHand

Prospective Real-World Evidence Study of the IpsiHand® System in Adult Stroke Survivors

Start: Sep 2025Est. completion: Jan 2028
N/ANot Yet Recruiting
NCT07106619City TherapeuticsIsokinetic Exercises

Effectiveness of Isokinetic Exercises in Proprioception for Post-stroke Patients

Start: Aug 2025Est. completion: Mar 2026
N/ARecruiting
NCT07208422Assembly BiosciencesVideo-based Task-specific Training

Task-Specific Self-Rehabilitation Training (TASSRET) Trial

Start: Jun 2025Est. completion: Feb 2026
N/ARecruiting
NCT06999122EMVisionBrain Scan

Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients

Start: Mar 2025Est. completion: Nov 2026
N/ARecruiting
NCT06772194AbbVieTaiwan Post-Stroke Disability Study

Taiwan Post-Stroke Disability Study

Start: Oct 2024Est. completion: Sep 20282,000 patients
N/ARecruiting
NCT06076928Design TherapeuticsBrain Computer Interface integrated HandyRehab platform

Brain Computer Interface (BCI) Integrated Wearable Hand Robotic Glove System for Upper Limb Stroke Rehabilitation

Start: Aug 2024Est. completion: Jan 2026
N/ARecruiting
NCT06457126Alliance PharmaceuticalsAttention Training Technique

Piloting the Attention Training Technique for Post-Stroke Emotionalism

Start: Jun 2024Est. completion: Aug 202514 patients
N/ANot Yet Recruiting
NCT06296628Design TherapeuticsMiraπ

Rehabilitation Device for Hand Mirror Therapy

Start: Apr 2024Est. completion: Apr 2025
N/ACompleted
NCT05965713NeuroLutionsNeurolutions IpsiHand System

National Fully Remote Use of IpsiHand Device in Hemiparetic Stroke

Start: Oct 2023Est. completion: Oct 2025
N/ACompleted
NCT05993221Providence TherapeuticsDeconstructing Post Stroke Hemiparesis

Deconstructing Post Stroke Hemiparesis

Start: Sep 2023Est. completion: Sep 2027
N/ARecruiting
NCT05672628Seed TherapeuticsOculus VR

The Feasibility, Usability, and Acceptability of Using the Oculus™ Virtual Reality Gaming Technology in Stroke Survivors for Upper Extremity and Cognitive Rehabilitation

Start: Mar 2023Est. completion: Jul 2024
N/ACompleted
NCT05395351Boehringer Ingelheimrt-PA

Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization

Start: Nov 2022Est. completion: Mar 2023113,035 patients
N/ACompleted
NCT05458908Siemens HealthineersNon-contrast cranial MDCT head scan

ProSPective Evaluation of Non-contrast sINe spiN Flat-dEtectoR CT for the Detection of Intracranial hemorrhageS

Start: Oct 2022Est. completion: Mar 2026
N/AActive Not Recruiting
NCT05401149Boehringer Ingelheimrt-PA

Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients

Start: Jul 2022Est. completion: Dec 20223,058 patients
N/ACompleted
NCT05395338Boehringer Ingelheimrt-PA

1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients

Start: Apr 2022Est. completion: Nov 202212,551 patients
N/ACompleted

Related Jobs in Neurology

Associate Director, HCP Marketing - Parkinson's Disease

AbbVie
Mettawa, IL
2h ago

Clinical Trial Manager/Senior Clinical Trial Manager

Axsome Therapeutics
New York, NY
3h ago
$130K - $150K/yr

Specialty Account Manager, Auvelity (Hammond, IN)

Axsome Therapeutics
Hammond, IN
15h ago
$100K - $150K/yr

Specialty Account Manager, Symbravo (Indianapolis N, IN)

Axsome Therapeutics
Indianapolis, IN
22h ago
$100K - $150K/yr

Specialty Account Manager, Sunosi (Indianapolis N, IN)

Axsome Therapeutics
Indianapolis, IN
22h ago
$110K - $150K/yr

Medical Science Liaison/Senior Medical Science Liaison, Migraine (Southeast)

Axsome Therapeutics
Miami, FL
Yesterday
$150K - $200K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs — potential near-term approvals
6 actively recruiting trials targeting 188,476 patients
30 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)Amyotrophic Lateral Sclerosis(77)